Deferasirox

證據等級: L5

預測適應症: 5 個

Deferasirox: From Chronic Iron Overload to HIV Infectious Disease

One-Sentence Summary

Deferasirox is an oral iron chelator, clinically established for managing chronic iron overload (e.g., transfusional iron overload). The TxGNN model predicts it may be effective for HIV Infectious Disease, currently supported only by 0 clinical trials and 2 publications, both at a preclinical/mechanistic level.

Quick Overview

Item	Content
Original Indication	Chronic iron overload (iron chelation therapy) — not documented in the evidence pack; based on established clinical knowledge of deferasirox
Predicted New Indication	HIV infectious disease
TxGNN Prediction Score	99.40%
Evidence Level	L4
Germany Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for deferasirox is not available in this evidence pack. Based on known clinical information, deferasirox is an oral iron chelator used to reduce chronic iron overload (e.g., in transfusion-dependent conditions), and mechanistically it may be relevant to any disease process where intracellular free iron availability plays a regulatory role.

The single mechanistic study supporting this prediction (PMID 34550543) shows that restricting endolysosomal iron increases HIV-1 Tat protein oligomerization and β-catenin expression, which in turn suppresses Tat-mediated transactivation of the HIV-1 LTR promoter — an in vitro finding regarding iron biology and HIV transcription. However, this study did not test deferasirox itself, nor was the effect validated in infected cells, animal models, or humans. The link between deferasirox's iron-chelating action and this pathway is therefore indirect and hypothesis-generating only.

The second reference (PMID 16529348) is a general "new drugs" overview article from 2006 that briefly mentions deferasirox alongside unrelated agents, with no HIV-specific content. Overall, the biological rationale is plausible in principle (iron metabolism intersects with several viral replication pathways), but there is no direct experimental or clinical evidence that deferasirox exerts anti-HIV activity.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34550543	2021	Mechanistic/In vitro	Journal of NeuroVirology	Endolysosomal iron restriction increases HIV-1 Tat oligomerization and β-catenin expression, thereby suppressing Tat-mediated HIV-1 LTR transactivation; deferasirox itself was not tested
16529348	2006	Review (general new-drug overview, not HIV-specific)	Journal of the American Pharmacists Association	Brief introductory overview of newly approved drugs including deferasirox; no HIV-related content

Germany Market Information

Deferasirox currently has no registered marketing authorizations in Germany within this evidence pack (market status: not marketed; total authorizations: 0).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence supporting an HIV indication for deferasirox is limited to a single in vitro mechanistic study that did not test the drug directly, with no clinical trials, no in vivo/animal validation, and no marketing authorization in Germany. This does not meet the threshold to advance to clinical evaluation.

To proceed, the following is needed:

Deferasirox-specific antiviral efficacy data (in vitro HIV infection models, then in vivo)
Confirmed mechanism of action (MOA) documentation from DrugBank or primary literature
TFDA/BfArM label data — key warnings, contraindications, and drug-drug interactions (currently all data gaps)
Original indication and licensing details to properly benchmark the repurposing rationale
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.